Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy

Surgical Site Infection Clinical Trial

— PALEXIS  

Official title:

Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy: a Randomized Single-blind Controlled Clinical Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03820648
• Other study ID #: CE 1369 cesc
• Status: Terminated
• Phase: N/A
• Start date: September 7, 2017
• Est. completion date: December 9, 2019

Study information

• Verified date: December 2019
• Source: Azienda Ospedaliera Universitaria Integrata Verona
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Surgical site infection (SSI) is a leading cause of preventable morbidity and mortality in North America and worldwide. This condition has consistently been reported to account for up to 25% of all healthcare-associated infections. In a cost analysis, SSIs post-pancreaticoduodenectomy (PD) dramatically increases the treatment costs. More importantly, postoperative wound infections delay postoperative adjuvant chemotherapy, which is indicated in the majority of patients undergoing PD for pancreatic cancer. Protective covers or 'wound protectors' are hypothesized to be an improvement over adhesive membrane barriers as they are believed to reduce intraoperative contamination while concomitantly preserving the temperature and humidity of the surgical wound. The aim of this study is to assess if the use of wound protector can reduce the wound infection rate in patients undergoing to PD.

Description:

Surgical site infection (SSI) is a leading cause of preventable morbidity and mortality in North America and worldwide. This condition has consistently been reported to account for up to 25% of all healthcare-associated infections. Prolonged hospitalization, more frequent hospital re-admissions after surgery and a greater than twofold increase in costs and mortality have consistently been associated with this condition over the past decade. The SSI is associated with an increased risk of postsurgical pain, poor wound healing and aesthetic results and an increased risk of incisional hernias. The literature shows an incidence rate of SSI at 30 days after surgery that reaches 51% of cases. In particular, the incidence of wound infection is 15%. In our experience, the rate of wound infection in patients undergoing Pancreaticoduodenectomy (PD) is 10%.

SSI is an infectious process that is localized to surgical incision level and it is classified as being either incisional or organ/space. Incisional SSI is further divided into those involving only skin and subcutaneous tissue (superficial incisional SSI) and those involving deeper soft tissues of the incision (deep incisional SSI).

In a cost analysis, SSIs post-PD dramatically increases the treatment costs. More importantly, postoperative wound infections delay postoperative adjuvant chemotherapy, which is indicated in the majority of patients undergoing PD for pancreatic cancer. During recent years there is also an increasing incidence of antibiotic-resistant pathogens in hospitals, so several studies have suggested primary or secondary prevention strategies to reduce SSI rate. In order to minimize the risk of SSI, various measures of perioperative care have already been adopted, including the cleaning of the skin, the hair removal of the intervention area, the prevention of intraoperative hypothermia and perioperative antibiotic therapy. However there are few studies on the effectiveness of surgical procedures for primary prevention to reduce the contamination in the surgical site, especially in patients undergoing major gastrointestinal surgery. The surgical procedures classified as contaminated or dirty (with a higher bacterial load within the surgical site and/or regarding gastrointestinal or biliary tracts) remain associated with an increased risk of SSI, about two times, compared to the interventions classified as clean or clean-contaminated. The PD is classified as surgery contaminated / dirty.

The use of adhesive membrane barriers over the skin of the surgical site emerged 50 years ago as a possible solution to minimize endogenous cross-contamination during surgery. The initial idea relied on the principle of reducing exposure of the surgical site to bacteria inherent in the surrounding skin or to airborne bacteria in the operating room. Major applicability was expected in clean surgeries, where the skin is considered the main source of bacteria. Unfortunately, however, no evidence in support of plastic adhesive drapes was found in a recently updated systematic review of randomized controlled trials (RCTs) including five studies and 3082 patients. In fact, a 23% increase in the risk of SSI was found in the group that received adhesive drapes. In the 1960s, other devices were described and then developed based on the concept of combining a non-traumatic surgical wound retractor with a protective membrane covering of the incisional margin in abdominal surgeries. Such protective covers or 'wound protectors' (WP) were hypothesized to be an improvement over adhesive membrane barriers as they were believed to reduce intraoperative contamination while concomitantly preserving the temperature and humidity of the surgical wound. In support of this hypothesis, early studies demonstrated reduced exposure of the surgical wound to enteric bacteria at the end of gastrointestinal operations. These results were further supported by several RCTs, which demonstrated that wound protectors were efficacious in reducing the incidence of incisional SSI as compared to usual care in patients undergoing gastrointestinal surgeries. A recently meta-analysis of RCTs on the WP enrolled 6 studies and 1008 patients, finding that the pooled estimated risk of SSI among patients fitted with wound protectors during surgery was 0.55 (95% CI 0.31 to 0.98) times the pooled estimated risk of SSI in control groups.

The aim of this study is to assess if the use of WP can reduce the wound infection rate in patients undergoing to PD.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 212
• Est. completion date: December 9, 2019
• Est. primary completion date: December 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Scheduled for elective PD

• Age = 18 years

• Ability of the subject to understand character and individual consequences of the clinical trial

• Written informed consent

Exclusion Criteria:

• Under 18 years of age

• Unable to sign informed consent

Related Conditions & MeSH terms

• Surgical Site Infection
• Surgical Wound Infection

Intervention

Device:
• Alexis
The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
• Standard 3M™ Steri-Drape 2
Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.

Locations

Country	Name	City	State
Italy	AOUI Verona	Verona

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera Universitaria Integrata Verona

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surgical site infection	Number of SSI onset in patients submitted to PD until the 30th day postoperative. This endpoint will be compared between the two groups.	30th day postoperative
Secondary	Device resistance	Number intraoperative device rupture in both groups. It will be also recorded the number of device lesions seen at the end of the surgical operation.	Intraoperative
Secondary	Treatment costs related to increased hospital stays due to SSI	Number of additional days to the average hospital stays (7 days) of the patients submitted to PD at our Institute, related to the onset of SSI until the 30th day postoperative	30th day postoperative
Secondary	Costs related to the use of additional antibiotics administered for the treatment of SSI	Evaluation of the total costs of the additional antibiotic therapy administered for the treatment of SSI, developed within the 30th day postoperative, in the two patient groups. It will be considered like the ex-factory price of the drug.	30th day postoperative